Blog

Netflix NFLX shares are overvalued, as suggested by a Value Score of C. The NFLX stock is trading at a forward 12-month price/sales (P/S) of 7.3X compared with the broader Zacks Consumer

Novo Nordisk NVO and its partner, The United Laboratories International Holdings Limited ("TUL"), jointly announced top-line data from a phase II study in China, evaluating UBT251, a novel triple

Investors might want to bet on Magnolia Oil & Gas Corp (MGY), as earnings estimates for this company have been showing solid improvement lately. The stock has already gained solid short-term price

EQT Corporation (EQT) could be a solid addition to your portfolio given a notable revision in the company's earnings estimates. While the stock has been gaining lately, the trend might continue

Digital healthcare continues to evolve across both direct-to-consumer and professional-focused platforms, with Hims & Hers Health, Inc. HIMS and Doximity, Inc. DOCS representing two distinct

Paychex, Inc. PAYX reported impressive third-quarter fiscal 2026 results, with both earnings and revenues beating the Zacks Consensus Estimate.

PAYX’s fiscal third-quarter earnings of $1.71 per

Shares of Ocugen OCGN declined 8.6% on Tuesday after the company announced 12-month data from the phase II ArMaDa study evaluating its novel modifier gene therapy, OCU410, for treating geographic

AirJoule Technologies Corporation AIRJ is slated to report its fourth-quarter 2025 results on March 30, after the closing bell.

The company’s earnings surprise history is impressive. It surpassed

If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider TD SYNNEX

Rave Restaurant Group, Inc. RAVE investors have been experiencing some short-term losses from the stock in recent months. Shares of this Dallas, TX-based operator of pizza restaurants have declined

BrightSpring Health Services, Inc. BTSG is built around a durable healthcare shift: more complex care moving out of hospitals and into the home and community. The company’s 2026 setup pairs that

BrightSpring Health Services, Inc. BTSG is coming off a strong finish to 2025, and the market is rewarding that momentum. The stock now trades at 24.5 times forward 12-month earnings per share

Bristol Myers Squibb BMY recently won FDA and European Commission (EC) approvals for the label expansion of its blockbuster immuno-oncology (IO) drug Opdivo.

The FDA approved Opdivo in combination

BrightSpring Health Services, Inc. BTSG enters 2026 with a business model built for one clear trend: more complex care moving out of hospitals and into the home. That shift expands demand for

PG&E (PCG) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most

First Bancorp (FBNC) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of

BCB Bancorp (BCBP) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting

Investors might want to bet on CMS Energy (CMS), as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of

Enbridge (ENB) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In "long context," investors will be essentially be "buying high, but hoping to sell even

Investors might want to bet on RF Industries, Ltd. (RFIL), as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces

Coherus Oncology (CHRS) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting

Investors might want to bet on EQT Corporation (EQT), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In "long context," investors will be essentially be "buying high, but hoping to sell even